Pharmaceutical MK4482 Molnupiravir Powder COVID-19 Molulife Tablet

Molnupiravir is an antiviral medication that has gained attention for its potential use in treating COVID-19 and other viral infections.

Molnupiravir is a prodrug, which means it is metabolized in the body into its active form. The active form of Molnupiravir works by inhibiting the replication of RNA viruses. It does this by causing mutations in the viral genetic material, which can lead to errors during viral replication and ultimately reduce the ability of the virus to reproduce.

Molnupiravir was originally developed as a potential treatment for influenza. However, its broad-spectrum antiviral activity has led to investigations into its effectiveness against other RNA viruses, including coronaviruses.

Molnupiravir, also known as MK-4482/EIDD-2801, is an antiviral medication with a unique mechanism of action. Its primary function is to inhibit viral replication by introducing errors during the copying process of the viral genetic material.

• Inhibition of Viral Replication: Molnupiravir is a prodrug that's metabolized into its active form in the body. It introduces errors into the virus's genetic code during replication, disrupting its ability to make accurate copies.
• Broad Spectrum Activity: Effective against various RNA viruses including influenza, coronaviruses (SARS-CoV-2), Ebola, and Venezuelan equine encephalitis virus.
• Reduction of Viral Load: By inhibiting viral replication, it reduces virus presence in the body, potentially leading to milder symptoms and shorter illness duration while lowering transmission risk.

• 1~25kgs packaging: Aluminium bag inside, Carton box outside.
• 25kgs packaging: Plastic bag inside, Fiber drum outside.